Skip navigation
Skip navigation

Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study Abstracts

Sanyal, Arun; Ratziu, Vlad; Harrison, Stephen A; Abdelmalek, Manal F; Aithal, Guruprasad P; Caballeria, Juan; Francque, Sven; Farrell, Geoffrey; Kowdley, Kris V; Craxi, Antonio; Simon, Krzysztof


Background: Cenicriviroc (CVC), an oral chemokine receptor CCR2/5 antagonist, has potent anti-inflammatory and antifibrotic activity in animal models of acute and chronic liver diseases. Its efficacy and safety as a treatment for non-alcoholic steatohepatitis (NASH) and liver fibrosis are being evaluated in adults at increased risk of progression to cirrhosis (CENTAUR; NCT02217475). Methods: Phase 2b, randomized, double-blind, placebo-controlled, ongoing 2-year multinational study;...[Show more]

CollectionsANU Research Publications
Date published: 2016
Type: Conference paper
Source: Hepatology


File Description SizeFormat Image
01_Sanyal_Cenicriviroc_placebo_for_the_2016.pdf96.37 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator